MDxHealth SA (MDXH.BR) Stock Fundamental Analysis

EBR:MDXH • BE0974461940

3.02 EUR
-0.12 (-3.76%)
Last: Dec 15, 2023, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to MDXH. MDXH was compared to 77 industry peers in the Biotechnology industry. MDXH may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, MDXH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year MDXH has reported negative net income.
MDXH.BR Yearly Net Income VS EBIT VS OCF VS FCFMDXH.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

  • The Return On Assets of MDXH (-51.61%) is worse than 63.64% of its industry peers.
  • Looking at the Return On Equity, with a value of -393.48%, MDXH is doing worse than 75.32% of the companies in the same industry.
Industry RankSector Rank
ROA -51.61%
ROE -393.48%
ROIC N/A
ROA(3y)-55.15%
ROA(5y)-64.23%
ROE(3y)-343.17%
ROE(5y)-262.12%
ROIC(3y)N/A
ROIC(5y)N/A
MDXH.BR Yearly ROA, ROE, ROICMDXH.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -100 -200 -300 -400

1.3 Margins

  • MDXH has a better Gross Margin (59.66%) than 64.94% of its industry peers.
  • In the last couple of years the Gross Margin of MDXH has declined.
  • MDXH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-6.79%
MDXH.BR Yearly Profit, Operating, Gross MarginsMDXH.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • MDXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MDXH has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for MDXH is higher compared to a year ago.
MDXH.BR Yearly Shares OutstandingMDXH.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M
MDXH.BR Yearly Total Debt VS Total AssetsMDXH.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -3.05, we must say that MDXH is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -3.05, MDXH is doing worse than 71.43% of the companies in the same industry.
  • A Debt/Equity ratio of 2.17 is on the high side and indicates that MDXH has dependencies on debt financing.
  • The Debt to Equity ratio of MDXH (2.17) is worse than 75.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.17
Debt/FCF N/A
Altman-Z -3.05
ROIC/WACCN/A
WACC6.93%
MDXH.BR Yearly LT Debt VS Equity VS FCFMDXH.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

  • MDXH has a Current Ratio of 2.43. This indicates that MDXH is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of MDXH (2.43) is comparable to the rest of the industry.
  • A Quick Ratio of 2.27 indicates that MDXH has no problem at all paying its short term obligations.
  • MDXH has a Quick ratio (2.27) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.43
Quick Ratio 2.27
MDXH.BR Yearly Current Assets VS Current LiabilitesMDXH.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The earnings per share for MDXH have decreased strongly by -16.81% in the last year.
  • MDXH shows a strong growth in Revenue. In the last year, the Revenue has grown by 66.59%.
  • MDXH shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.77% yearly.
EPS 1Y (TTM)-16.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
Revenue 1Y (TTM)66.59%
Revenue growth 3Y46.47%
Revenue growth 5Y-1.77%
Sales Q2Q%73.48%

3.2 Future

  • Based on estimates for the next years, MDXH will show a very strong growth in Earnings Per Share. The EPS will grow by 51.91% on average per year.
  • MDXH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.69% yearly.
EPS Next Y-6519.8%
EPS Next 2Y-619.83%
EPS Next 3Y-49.87%
EPS Next 5Y51.91%
Revenue Next Year84.81%
Revenue Next 2Y47.5%
Revenue Next 3Y43.11%
Revenue Next 5Y27.69%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MDXH.BR Yearly Revenue VS EstimatesMDXH.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
MDXH.BR Yearly EPS VS EstimatesMDXH.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MDXH. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDXH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDXH.BR Price Earnings VS Forward Price EarningsMDXH.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDXH.BR Per share dataMDXH.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • MDXH's earnings are expected to decrease with -49.87% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-619.83%
EPS Next 3Y-49.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • MDXH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

MDxHealth SA

EBR:MDXH (12/15/2023, 7:00:00 PM)

3.02

-0.12 (-3.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap82.41M
Revenue(TTM)89.55M
Net Income(TTM)-70.04M
Analysts86.67
Price Target8.4 (178.15%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)86.3%
Min EPS beat(2)82.17%
Max EPS beat(2)90.44%
EPS beat(4)4
Avg EPS beat(4)88.67%
Min EPS beat(4)82.17%
Max EPS beat(4)98.56%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)64.31%
Min Revenue beat(2)6.24%
Max Revenue beat(2)122.37%
Revenue beat(4)4
Avg Revenue beat(4)65.41%
Min Revenue beat(4)6.24%
Max Revenue beat(4)122.37%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)814.71%
PT rev (3m)814.71%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-889.37%
EPS NY rev (3m)-731.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.5%
Revenue NY rev (3m)1.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.01
P/FCF N/A
P/OCF N/A
P/B 5.1
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.68
EYN/A
EPS(NY)-4.7
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.98
BVpS0.59
TBVpS-2.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.61%
ROE -393.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.66%
FCFM N/A
ROA(3y)-55.15%
ROA(5y)-64.23%
ROE(3y)-343.17%
ROE(5y)-262.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-6.79%
F-ScoreN/A
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 2.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.43
Quick Ratio 2.27
Altman-Z -3.05
F-ScoreN/A
WACC6.93%
ROIC/WACCN/A
Cap/Depr(3y)43.52%
Cap/Depr(5y)35.7%
Cap/Sales(3y)6.07%
Cap/Sales(5y)4.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
EPS Next Y-6519.8%
EPS Next 2Y-619.83%
EPS Next 3Y-49.87%
EPS Next 5Y51.91%
Revenue 1Y (TTM)66.59%
Revenue growth 3Y46.47%
Revenue growth 5Y-1.77%
Sales Q2Q%73.48%
Revenue Next Year84.81%
Revenue Next 2Y47.5%
Revenue Next 3Y43.11%
Revenue Next 5Y27.69%
EBIT growth 1Y-41.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.18%
EBIT Next 3Y24.82%
EBIT Next 5Y22.55%
FCF growth 1Y-63.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.31%
OCF growth 3YN/A
OCF growth 5YN/A

MDxHealth SA / MDXH.BR FAQ

Can you provide the ChartMill fundamental rating for MDxHealth SA?

ChartMill assigns a fundamental rating of 2 / 10 to MDXH.BR.


What is the valuation status of MDxHealth SA (MDXH.BR) stock?

ChartMill assigns a valuation rating of 0 / 10 to MDxHealth SA (MDXH.BR). This can be considered as Overvalued.


How profitable is MDxHealth SA (MDXH.BR) stock?

MDxHealth SA (MDXH.BR) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for MDXH stock?

The Earnings per Share (EPS) of MDxHealth SA (MDXH.BR) is expected to decline by -6519.8% in the next year.